Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A US Real-World Retrospective Cohort Study

Shreekant Parasuraman, Anna Teschemaker, Jonathan K. Kish, Kristin M. Savill, Philomena Colucci

Blood (2022) 140 (Supplement 1): 6854–6855.

https://doi.org/10.1182/blood-2022-162320

Published: 2022

Journal Articles

Realmind: A Prospective, Multicenter, Observational Study of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplant

Christopher R. Flowers, John M. Burke, Mirko Vukcevic, Susan Snodgrass, Shreekant Parasuraman, Thomas Büchele, Nuwan C. Kurukulasuriya

Blood (2021) 138 (Supplement 1): 5010.

https://doi.org/10.1182/blood-2021-148292

Published: 2021

Journal Articles

Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States

Srdan Verstovsek, MD PhD, Jingbo Yu, MD PhD, Robyn M. Scherber, MD, Shivani Pandya, MS, Christopher Dieyi, MPH, Chien-Cheng Chen, MS, Shreekant Parasuraman, BPharm, PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141090

Published: 2020

Journal Articles

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-141370

Published: 2020

Journal Articles

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Jingbo Yu, MD PhD, Shreekant Parasuraman, BPharm, PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-141333

Published: 2020

Journal Articles

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Srdan Verstovsek, MD PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Shambhavi Kumar, MS, Ann Xi, PharmD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140820

Published: 2020

Journal Articles

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ivy Altomare, MD, Anna Nguyen, PharmD, MPH, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Jonathan K. Kish, PhD MPH, Kevin Lord, PhD MHS, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 4192.

https://doi.org/10.1182/blood-2019-127442

Published: 2019

Journal Articles

Elevated White Blood Cell Levels and Thrombotic Events in Patients with Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data

Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, PhD, Dilan Chamikara Paranagama, PhD, Sulena Shrestha, MPH, Li Wang, PhD, Onur Baser, PhD, Robyn Marie Scherber, MD MPH

Blood (2018) 132 (Supplement 1): 1758.

https://doi.org/10.1182/blood-2018-99-118451

Published: 2018

Journal Articles

Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study

Anas Al-Janadi, MD, Ruben A. Mesa, MD FACP, Philomena Colucci, DO, MS, Shreekant Parasuraman, BPharm, PhD, Dilan Chamikara Paranagama, PhD, Michael Richard Grunwald, MD

Blood (2018) 132 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2018-99-111986

Published: 2018

Journal Articles

Disease Characteristics of Minority Patient Populations with Polycythemia Vera: An Analysis from the Reveal Study

Ivy Altomare, MD, Philomena Colucci, DO, MS, Shreekant Parasuraman, BPharm, PhD, Dilan Chamikara Paranagama, PhD, Anas Al-Janadi, MD

Blood (2018) 132 (Supplement 1): 4735.

https://doi.org/10.1182/blood-2018-99-112530

Published: 2018

Journal Articles

Impact of Myeloproliferative Neoplasms on Patients' Employment and Income: Findings from the Living with MPN Survey

Simon Condliffe, PhD MS, Jingbo Yu, PhD, Dilan Chamikara Paranagama, PhD, Shreekant Parasuraman, BPharm, PhD

Blood (2018) 132 (Supplement 1): 2250.

https://doi.org/10.1182/blood-2018-99-115345

Published: 2018

Journal Articles

Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study

Ivy Altomare, MD, Aaron T. Gerds, MDMS, David Lessen, MD, Philomena Colucci, DO, MS, Shreekant Parasuraman, BPharm, PhD, Dilan Chamikara Paranagama, PhD, Ruben A. Mesa, MD FACP

Blood (2018) 132 (Supplement 1): 2259.

https://doi.org/10.1182/blood-2018-99-112937

Published: 2018

Journal Articles

Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey

Jingbo Yu, MHA, PhD, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Ahmad Naim, MD, David Dubinski, MBA, Andrew Bai, MS, Ruben Mesa, MD FACP

Blood (2016) 128 (22): 4256.

https://doi.org/10.1182/blood.V128.22.4256.4256

Published: 2016

Journal Articles

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Brady L. Stein, MD, Ahmad Naim, MD, Michael R. Grunwald, MD, Alison R. Moliterno, MD, Stephen T. Oh, MD PhD, Dilan Paranagama, PhD, Joseph A. Cordaro, PharmD, MBA, Hao Sun, MS, Shreekant Parasuraman, BPharm, PhD, Ralph V. Boccia, Ruben Mesa, MD FACP

Blood (2016) 128 (22): 1934.

https://doi.org/10.1182/blood.V128.22.1934.1934

Published: 2016

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

Treatment Patterns and Hydroxyurea Response Among Patients with Polycythemia Vera

Shreekant Parasuraman, PhD, Marco DiBonaventura, PhD, Kelly Reith, MS,MBA, Kristen Concialdi, BA

Blood (2014) 124 (21): 1852.

https://doi.org/10.1182/blood.V124.21.1852.1852

Published: 2014

NARROW

Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A US Real-World Retrospective Cohort Study

Realmind: A Prospective, Multicenter, Observational Study of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplant

Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Elevated White Blood Cell Levels and Thrombotic Events in Patients with Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data

Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study

Disease Characteristics of Minority Patient Populations with Polycythemia Vera: An Analysis from the Reveal Study

Impact of Myeloproliferative Neoplasms on Patients' Employment and Income: Findings from the Living with MPN Survey

Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study

Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Treatment Patterns and Hydroxyurea Response Among Patients with Polycythemia Vera

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only